Crestor (Rosuvastatin) Cost in Nebraska 2026: Prices, Insurance, and Savings

What Does Crestor Actually Cost in Nebraska Right Now?

The average cash price for generic rosuvastatin at Nebraska retail pharmacies sits at approximately $15 per month in 2026 for standard doses (10 mg or 20 mg tablets, 30-day supply). Brand-name Crestor from AstraZeneca carries a manufacturer list price of $290 per month, though virtually no patient paying out of pocket should pay this amount given widespread generic availability.

Pricing varies by pharmacy and location. Omaha and Lincoln metro pharmacies tend to price slightly lower due to competition, while rural pharmacies may charge $18 to $25 for the same generic supply. Large chains (Hy-Vee, Walgreens, CVS) typically offer rosuvastatin on their $4 to $15 generic drug lists, making it one of the least expensive statins available 1.

The price collapse since Crestor's patent expiration in 2016 has been dramatic. A 2023 analysis published in the Journal of the American Heart Association found that generic statin prices fell 95% within five years of patent expiration for high-volume molecules like rosuvastatin and atorvastatin 2. Nebraska patients benefit from this trend. The $15 average reflects a competitive retail market where multiple generic manufacturers (Aurobindo, Teva, Hikma, Sun Pharma) supply Nebraska wholesalers.

Nebraska Medicaid and Rosuvastatin Coverage

Nebraska Medicaid does not cover brand-name Crestor. The Nebraska Drug Utilization Review (DUR) Board excludes Crestor from the preferred drug list when a therapeutically equivalent generic exists at lower cost.

Generic rosuvastatin, however, is covered under Nebraska's Medicaid managed-care organizations (Heritage Health plans administered by UnitedHealthcare Community Plan, Healthy Blue, and Molina Healthcare). Each MCO places generic rosuvastatin on Tier 1 (preferred generic), which means $0 to $3 copays for most adult beneficiaries 3.

Prior authorization is not required for generic rosuvastatin at doses up to 40 mg daily. The 40 mg dose may require documentation of LDL response to lower doses in some Heritage Health plans, but this is not universal. Patients prescribed brand Crestor by a physician will receive an automatic substitution to generic rosuvastatin at the pharmacy unless the prescriber writes "Dispense As Written" (DAW), which Medicaid will not reimburse without a documented medical necessity exception.

For Nebraska Medicaid enrollees who need a statin, the practical cost is near zero. This aligns with federal requirements under the Affordable Care Act's preventive services mandate, which requires coverage of USPSTF-recommended statin therapy for adults aged 40 to 75 with cardiovascular risk factors 4.

Commercial Insurance Coverage in Nebraska

Most commercial health plans sold in Nebraska (Blue Cross Blue Shield of Nebraska, Medica, UnitedHealthcare, Aetna) cover generic rosuvastatin at Tier 1 copays ranging from $0 to $15 per month. Brand Crestor, when covered at all, sits on Tier 3 (non-preferred brand) with copays of $40 to $75 or coinsurance of 25% to 50%.

Step therapy requirements are uncommon for rosuvastatin because it is already a generic. Some high-deductible health plans (HDHPs) require patients to pay full cost until the deductible is met, but even then, the $15 generic price makes this manageable compared to brand alternatives.

Medicare Part D plans in Nebraska follow a similar pattern. The 2026 Part D redesign caps out-of-pocket spending at $2,000 annually and eliminates the coverage gap (the "donut hole"). For rosuvastatin, most Part D plans assign it to Tier 1 with copays of $1 to $10 5.

Nebraska employers with self-funded health plans often include rosuvastatin on zero-copay preventive drug lists. The ACA preventive services requirement applies to fully insured plans, and many self-funded plans voluntarily follow the same formulary logic. If your employer plan charges a copay for rosuvastatin, verify whether your plan classifies it as preventive (for primary prevention in eligible patients) or therapeutic (for secondary prevention after a cardiovascular event). The distinction affects cost-sharing.

The JUPITER Trial: Why Rosuvastatin Became a Prevention Standard

Rosuvastatin's clinical evidence base drove its position as one of the most prescribed statins in the U.S., including Nebraska. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), published in the New England Journal of Medicine in 2008, randomized 17,802 apparently healthy men and women with LDL cholesterol levels below 130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP ≥ 2.0 mg/L) to rosuvastatin 20 mg daily versus placebo 1.

The trial was stopped early at a median follow-up of 1.9 years. Rosuvastatin reduced the primary endpoint (first major cardiovascular event) by 44% (hazard ratio 0.56 to 95% CI 0.46 to 0.69, P<0.00001). LDL cholesterol fell 50%, and hsCRP decreased 37%.

Dr. Paul Ridker, the trial's principal investigator at Brigham and Women's Hospital, stated: "These data suggest that statin therapy may have a role in the primary prevention of cardiovascular events among persons who do not have hyperlipidemia but who have elevated levels of high-sensitivity C-reactive protein."

The American College of Cardiology/American Heart Association (ACC/AHA) 2018 cholesterol guidelines incorporated JUPITER's findings into their risk-enhancement framework, listing elevated hsCRP as a risk-enhancing factor that favors initiating statin therapy in borderline-risk patients 6. Nebraska clinicians prescribing rosuvastatin for primary prevention rely on this evidence base.

Compounded Rosuvastatin in Nebraska: Legality and Access

Compounded rosuvastatin is legal in Nebraska through licensed 503A compounding pharmacies. Under the Federal Food, Drug, and Cosmetic Act (Section 503A), pharmacies may compound patient-specific prescriptions using bulk rosuvastatin calcium powder when a valid prescription exists and the compound is prepared by a licensed pharmacist 7.

Nebraska does not impose additional state-level restrictions on 503A statin compounding beyond federal requirements. The Nebraska Department of Health and Human Services licenses compounding pharmacies under the Pharmacy Practice Act (Neb. Rev. Stat. § 38-2870).

Why would a patient choose compounded rosuvastatin when the generic costs $15? Three scenarios arise in practice. First, patients needing non-standard doses (e.g., 7.5 mg or 15 mg for those experiencing dose-dependent side effects) that commercial manufacturers do not produce. Second, patients requiring dye-free or filler-free formulations due to excipient sensitivities. Third, patients enrolled in telehealth or direct-primary-care programs that bundle compounded medications into membership fees, effectively reducing the per-unit cost to $0 beyond the membership.

Some Nebraska compounding pharmacies affiliated with telehealth platforms offer rosuvastatin at no additional cost as part of a subscription model. The clinical equivalence of compounded statins depends on the pharmacy's quality assurance protocols. Patients should verify their 503A pharmacy holds current Nebraska Board of Pharmacy licensure and undergoes regular potency testing.

Telehealth Prescribing of Rosuvastatin in Nebraska

Nebraska permits telehealth prescribing of rosuvastatin statewide. The Nebraska Telehealth Act (LB 400, enacted 2021) allows licensed prescribers to initiate controlled and non-controlled medications via synchronous audio-video visits without requiring an in-person visit first 8.

Rosuvastatin is a non-controlled prescription medication. Any Nebraska-licensed physician, nurse practitioner, or physician assistant may prescribe it after a telehealth evaluation that includes reviewing lipid panels and cardiovascular risk assessment. Lab orders for lipid panels can be sent to any Nebraska-based laboratory (Quest, LabCorp, or hospital-affiliated labs) prior to the telehealth visit.

Multiple national and regional telehealth platforms serve Nebraska patients for statin management. The workflow is straightforward: patient completes intake, uploads or completes labs, clinician reviews results and cardiovascular risk factors, and a prescription is transmitted to the patient's preferred Nebraska pharmacy. Turn-around from visit to filled prescription typically runs 24 to 72 hours.

For patients in rural Nebraska counties without nearby physicians (a significant portion of the state's 93 counties), telehealth removes a genuine access barrier. The 2024 ACC Expert Consensus on telehealth for cardiovascular risk management endorsed virtual statin initiation and titration as clinically appropriate when baseline labs are available 9.

Discount Programs and Savings Cards

Several programs reduce rosuvastatin costs for Nebraska patients who lack insurance or face high copays.

Manufacturer savings programs. AstraZeneca's savings card applies only to brand Crestor and is rarely needed given generic pricing. Generic manufacturers do not typically offer patient savings cards because wholesale competition already drives prices below $20.

Pharmacy discount programs. Hy-Vee's $4 generic list includes rosuvastatin (select doses). Walmart's $4/$10 generic program covers rosuvastatin 5 mg, 10 mg, and 20 mg (30-day and 90-day supplies). Costco Pharmacy (Omaha and Lincoln locations) prices generic rosuvastatin at $6 to $9 for 90 tablets without requiring membership for pharmacy purchases (per state pharmacy access laws).

GoodRx, RxSaver, and similar aggregators. These platforms show Nebraska pharmacy-specific pricing and offer free discount coupons. Typical coupon prices for rosuvastatin 20 mg #30 range from $8 to $14 at Nebraska pharmacies. The coupons cannot be combined with insurance but may beat copays on high-deductible plans.

340B pharmacies. Nebraska's Federally Qualified Health Centers (FQHCs) and certain hospital outpatient pharmacies participate in the 340B Drug Pricing Program. Eligible patients (those meeting income or uninsured criteria) can access rosuvastatin at 340B pricing, often $0 to $5 per month 10.

Nebraska prescription assistance. The state does not operate a standalone prescription assistance program for statins, but NeedyMeds and the Partnership for Prescription Assistance maintain directories of available programs by drug and state.

Rosuvastatin Dosing and What Affects Your Cost

Rosuvastatin is FDA-approved at doses of 5 mg, 10 mg, 20 mg, and 40 mg once daily 11. The starting dose for most adults is 10 mg or 20 mg daily, with 40 mg reserved for patients who do not reach LDL targets on lower doses.

Cost differences between doses at Nebraska pharmacies are minimal for generic rosuvastatin. Most pharmacies charge the same price regardless of tablet strength because all strengths share the same National Drug Code pricing tier from wholesalers. A 5 mg tablet costs the same as a 40 mg tablet in the generic market.

This means dose escalation does not increase out-of-pocket cost for most Nebraska patients. It also means pill-splitting (purchasing 40 mg tablets and splitting them for a 20 mg dose) offers no savings advantage, unlike some other medications.

The 2018 ACC/AHA guidelines categorize rosuvastatin 20 mg to 40 mg as "high-intensity" statin therapy (expected LDL reduction ≥ 50%) and rosuvastatin 5 mg to 10 mg as "moderate-intensity" therapy (expected LDL reduction 30% to 49%) 6. Patients with established atherosclerotic cardiovascular disease (ASCVD), LDL ≥ 190 mg/dL, or diabetes aged 40 to 75 are candidates for high-intensity therapy per guideline recommendations.

How Nebraska Compares to Neighboring States

Generic rosuvastatin pricing in Nebraska ($15 average) is consistent with neighboring Great Plains states. Iowa, Kansas, South Dakota, and Missouri report similar averages of $12 to $18 per month. Colorado trends slightly lower at $11 to $14, likely reflecting denser pharmacy competition along the Front Range.

Medicaid coverage varies more significantly. Iowa Medicaid covers generic rosuvastatin without prior authorization. Kansas Medicaid requires it for doses above 20 mg. South Dakota Medicaid covers all generic statin doses at preferred tier. Nebraska's exclusion of brand Crestor but coverage of generic rosuvastatin is the standard Medicaid approach in 2026, as no state Medicaid program has clinical justification to pay $290 for a branded product with multiple AB-rated generics available.

The 2022 IQVIA Institute report found that generic statins saved the U.S. healthcare system $19.4 billion annually compared to brand pricing, with per-patient savings exceeding $3,000 per year for rosuvastatin specifically 12.

Safety Monitoring and Lab Costs to Factor In

Beyond the drug itself, Nebraska patients should budget for monitoring labs. The ACC/AHA guidelines recommend a fasting lipid panel 4 to 12 weeks after statin initiation or dose change, then every 3 to 12 months based on clinical need 6.

A basic lipid panel at Nebraska commercial labs costs $20 to $50 without insurance (Quest Diagnostics Nebraska locations quote $39.99 for a standard lipid panel as a self-pay price). With insurance, this is typically covered as preventive care at no cost if ordered for cardiovascular risk assessment.

Hepatic transaminase monitoring (ALT) at baseline is recommended but routine periodic monitoring is no longer required per the 2012 FDA label update for statins. The FDA removed the recommendation for routine liver enzyme monitoring after post-marketing data showed serious liver injury with statins is rare (approximately 1 per 100,000 patient-years) 11.

Creatine kinase (CK) testing is not routinely recommended but should be obtained if a patient reports muscle symptoms. Myopathy occurs in fewer than 0.1% of rosuvastatin users, and rhabdomyolysis in fewer than 0.01%, based on post-marketing surveillance data 13.

The total annual cost of rosuvastatin therapy in Nebraska, including the drug ($180 per year at $15/month) plus two lipid panels ($80) and one office or telehealth visit copay ($25 to $50), runs approximately $285 to $310 for an uninsured cash-pay patient. For insured patients with preventive coverage, the annual out-of-pocket cost may be $0 to $36 (copays only).